252 related articles for article (PubMed ID: 20421512)
1. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine implants (Probuphine) for opioid dependence.
Med Lett Drugs Ther; 2016 Jul; 58(1499):94-5. PubMed ID: 27403784
[No Abstract] [Full Text] [Related]
5. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
Gruber VA; Rainey PM; Moody DE; Morse GD; Ma Q; Prathikanti S; Pade PA; Alvanzo AA; McCance-Katz EF
Clin Infect Dis; 2012 Feb; 54(3):414-23. PubMed ID: 22100576
[TBL] [Abstract][Full Text] [Related]
6. The diverse clinical uses of opioid receptor drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
[TBL] [Abstract][Full Text] [Related]
7. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
Clarke S; Mulcahy F; Bergin C; Reynolds H; Boyle N; Barry M; Back DJ
Clin Infect Dis; 2002 Apr; 34(8):1143-5. PubMed ID: 11915005
[TBL] [Abstract][Full Text] [Related]
8. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
[TBL] [Abstract][Full Text] [Related]
9. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Orman JS; Keating GM
Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
[TBL] [Abstract][Full Text] [Related]
12. Transfer from high dose methadone to buprenorphine/naloxone.
Wallace M
Aust Nurs J; 2011 Jul; 19(1):42-3. PubMed ID: 21853690
[No Abstract] [Full Text] [Related]
13. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.
DeVido J; Connery H; Hill KP
J Opioid Manag; 2015; 11(4):363-6. PubMed ID: 26312963
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.
Hulskotte EG; Bruce RD; Feng HP; Webster LR; Xuan F; Lin WH; O'Mara E; Wagner JA; Butterton JR
Eur J Clin Pharmacol; 2015 Mar; 71(3):303-11. PubMed ID: 25666027
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute pain in opioid tolerant patients.
Bean HK; Gannon R
Conn Med; 2010 Mar; 74(3):143-8. PubMed ID: 20391820
[No Abstract] [Full Text] [Related]
16. [Practical problems associated with long-term opioid therapy].
Bell RF
Tidsskr Nor Laegeforen; 1997 May; 117(12):1786-7. PubMed ID: 9213988
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
18. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
[No Abstract] [Full Text] [Related]
19. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder.
Herring AA; Schultz CW; Yang E; Greenwald MK
Am J Emerg Med; 2019 Dec; 37(12):2259-2262. PubMed ID: 31239086
[No Abstract] [Full Text] [Related]
20. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
